Compare FPH & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | TMCI |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.0M | 292.0M |
| IPO Year | 2013 | 2021 |
| Metric | FPH | TMCI |
|---|---|---|
| Price | $4.55 | $4.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 220.4K | 188.0K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $110,020,000.00 | ★ $212,690,000.00 |
| Revenue This Year | $1,459.63 | N/A |
| Revenue Next Year | $5.38 | $6.88 |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $4.20 | $1.17 |
| 52 Week High | $6.47 | $6.92 |
| Indicator | FPH | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 51.04 |
| Support Level | $4.20 | $3.82 |
| Resistance Level | $5.18 | $4.67 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 66.33 | 61.84 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.